Arrowhead Pharmaceuticals secured FDA approval for plozasiran (Redemplo) to treat familial chylomicronemia syndrome, marking the RNAi company’s transition to commercial stage and setting up direct competition with Ionis. Arrowhead launched Redemplo with a materially lower list price than its rival, signaling an aggressive commercial pricing strategy. Approval provides a second therapeutic option in a rare lipid disorder and validates RNA interference approaches beyond earlier niche indications. The pricing move aims to pressure incumbents and accelerate patient access but could trigger payer pushback and margin compression across rare‑disease RNA therapeutics. Investors and industry watchers will track uptake, reimbursement decisions and whether the pricing stance reshapes how RNA medicines are valued and negotiated in orphan diseases.